Sercan Y. Aksoy

Ankara, 06230, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 247 publications

Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers.

Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers.

Journal: Medicina (Kaunas, Lithuania)

Published: June 08, 2026

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Journal: Current oncology (Toronto, Ont.)

Published: May 02, 2026

Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.

Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.

Journal: Immunotherapy

Published: April 21, 2026

Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 12, 2026

Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer.

Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer.

Journal: Experimental hematology & oncology

Published: February 19, 2026

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Journal: Breast (Edinburgh, Scotland)

Published: January 21, 2026

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Journal: Breast (Edinburgh, Scotland)

Published: January 21, 2026

Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort Study.

Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort Study.

Journal: Journal of clinical medicine

Published: January 11, 2026

Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study.

Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study.

Journal: Scientific reports

Published: January 09, 2026

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study.

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study.

Journal: Scientific reports

Published: January 07, 2026

Elacestrant in metastatic breast cancer: current advancements and future perspectives.

Elacestrant in metastatic breast cancer: current advancements and future perspectives.

Journal: Expert review of anticancer therapy

Published: December 29, 2025

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study.

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study.

Journal: Therapeutic advances in medical oncology

Published: December 19, 2025

Showing 1-12 of 247

Last Updated: 09/26/2026